Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Local Institution, Torino

Local Institution, Rostock

St. Agnes Healthcare, Inc., Baltimore

Local Institution, Lübeck

Promedica Hematology & Oncology Assoicates, Sylvania

Local Institution, Florence

Local Institution, Cologne

Local Institution, Vandœuvre-lès-Nancy

Local Institution, Lille

Local Institution, Mannheim

Local Institution, Pierre-Bénite

Local Institution, Pringy

The University Of Texas Md Anderson Cancer Center, Houston

Local Institution, Napoli

Pacific Cancer Medical Center, Anaheim

Local Institution, Créteil

Local Institution, Catania

Cancer Center Of Central Connecticut, Southington

Local Institution, Jena

Local Institution, Roma

Local Institution, Roma

Local Institution, Seoul